Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

First patient randomised on the ISAP study

DTU

ISAP trial team outside the Oxford Health building

We reached a milestone today with the first participant randomisation visit for the ISAP trial. ISAP investigates the effect of oral semaglutide compared with placebo on the brain in individuals at risk for Alzheimer’s disease.

Thank you to the study participants, Oxford Health NIHR Clinical Research Facility, Dementias Platform UK, Oxford Health Biomedical Research Centre, and the funder Novo Nordisk who supported this investigator initiated study.

[More information about the ISAP trial]

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Under-40s diagnosed with type 2 diabetes have a mortality rate four times higher than the general population

People diagnosed with type 2 diabetes before 40 years of age, have nearly four times the risk of death compared with the general UK population, a new study carried out at the University of Oxford’s Radcliffe Department of Medicine has found.

Hydroxychloroquine provides moderate COVID-19 prevention

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life

The LEGEND-D Trial – which aims to prevent low blood sugar levels in type 1 diabetes – is open to recruitment

DTU to run clinical trial for Dementias Platform UK in nationwide bid to revolutionise dementia diagnosis using blood tests